Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integrative Transcriptomic and Single-Cell Protein Characterization of Colorectal Carcinoma Delineates Distinct Tumor Immune Microenvironments Associated with Overall Survival.
Hissong E, Bhinder B, Kim J, Ohara K, Ravichandran H, Assaad MA, Elsoukkary S, Shusterman M, Khan U, Eng KW, Bareja R, Manohar J, Sigouros M, Rendeiro AF, Jessurun J, Ocean AJ, Sboner A, Elemento O, Mosquera JM, Shah MA. Hissong E, et al. Among authors: bhinder b. Res Sq [Preprint]. 2024 Jul 25:rs.3.rs-4751101. doi: 10.21203/rs.3.rs-4751101/v1. Res Sq. 2024. PMID: 39108491 Free PMC article. Preprint.
The Orphan G Protein-Coupled Receptor GPR52 is a Novel Regulator of Breast Cancer Multicellular Organization.
Hanif SZ, Au CC, Torregroza I, Jannath SY, Fabiha T, Bhinder B, Washburn M, Devost D, Liu S, Bhardwaj P, Evans T, Anand PK, Tarran R, Palikhe S, Elemento O, Dow L, Blenis J, Hébert TE, Brown KA. Hanif SZ, et al. Among authors: bhinder b. bioRxiv [Preprint]. 2024 Jul 23:2024.07.22.604482. doi: 10.1101/2024.07.22.604482. bioRxiv. 2024. PMID: 39091857 Free PMC article. Preprint.
The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.
Ohara K, Rendeiro AF, Bhinder B, Eng KW, Ravichandran H, Nguyen D, Pisapia D, Vosoughi A, Fernandez E, Shohdy KS, Manohar J, Beg S, Wilkes D, Robinson BD, Khani F, Bareja R, Tagawa ST, Ouseph MM, Sboner A, Elemento O, Faltas BM, Mosquera JM. Ohara K, et al. Among authors: bhinder b. Nat Commun. 2024 Mar 18;15(1):2009. doi: 10.1038/s41467-024-46320-w. Nat Commun. 2024. PMID: 38499531 Free PMC article.
Cysteine induces mitochondrial reductive stress in glioblastoma through hydrogen peroxide production.
Noch EK, Palma L, Yim I, Bullen N, Barnett D, Walsh A, Bhinder B, Benedetti E, Krumsiek J, Gurvitch J, Khwaja S, Atlas D, Elemento O, Cantley LC. Noch EK, et al. Among authors: bhinder b. Proc Natl Acad Sci U S A. 2024 Feb 20;121(8):e2317343121. doi: 10.1073/pnas.2317343121. Epub 2024 Feb 15. Proc Natl Acad Sci U S A. 2024. PMID: 38359293 Free PMC article.
The nuclear factor ID3 endows macrophages with a potent anti-tumour activity.
Deng Z, Loyher PL, Lazarov T, Li L, Shen Z, Bhinder B, Yang H, Zhong Y, Alberdi A, Massague J, Sun JC, Benezra R, Glass CK, Elemento O, Iacobuzio-Donahue CA, Geissmann F. Deng Z, et al. Among authors: bhinder b. Nature. 2024 Feb;626(8000):864-873. doi: 10.1038/s41586-023-06950-4. Epub 2024 Feb 7. Nature. 2024. PMID: 38326607 Free PMC article.
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P, Christos PJ, Saxena A, Elemento O, Bhinder B, Ager C, Amin AD, Sanfilippo NJ, Mittal V, Borczuk AC, Formenti SC, Izar B, McGraw TE. Altorki NK, et al. Among authors: bhinder b. Nat Commun. 2024 Jan 3;15(1):225. doi: 10.1038/s41467-023-44575-3. Nat Commun. 2024. PMID: 38172131 Free PMC article. No abstract available.
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P, Christos PJ, Saxena A, Elemento O, Bhinder B, Ager C, Amin AD, Sanfilippo NJ, Mittal V, Borczuk AC, Formenti SC, Izar B, McGraw TE. Altorki NK, et al. Among authors: bhinder b. Nat Commun. 2023 Dec 19;14(1):8435. doi: 10.1038/s41467-023-44195-x. Nat Commun. 2023. PMID: 38114518 Free PMC article.
Co-design of patient information leaflets for germline predisposition to cancer: recommendations for clinical practice from the UK Cancer Genetics Group (UKCGG), Cancer Research UK (CRUK) funded CanGene-CanVar Programme and the Association of Genetic Nurse Counsellors (AGNC).
Kohut K, Speight B, Young J, Way R, Wiggins J, Monje-Garcia L, Eccles DM, Foster C, Turner L, Snape K, Hanson H; CanGene-CanVar Patient Reference Panel; Consensus Meeting Participants. Kohut K, et al. J Med Genet. 2024 Jan 19;61(2):142-149. doi: 10.1136/jmg-2023-109440. J Med Genet. 2024. PMID: 38050080 Free article.
56 results